Tislelizumab: An investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
Tislelizumab: An investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
Expert Opin Investig Drugs. 2020 Oct 12;:
Authors: Liu SY, Wu YL
Abstract
INTRODUCTION: Non-small cell lung cancer (NSCLC) accounts for most lung cancers worldwide and has a poor prognosis at later stages; programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have provided promising new treatment approaches for these patients. Tislelizumab, an anti-PD-1 monoclonal antibody, was engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab has demonstrated clinical activity and is approved in China for treatment of previously treated classical Hodgkin lymphoma and previously treated metastatic PD-L1-high urothelial carcinoma.
AREAS COVERED: This review summarizes the clinical efficacy, safety, and tolerability of tislelizumab in patients with NSCLC and examines the mechanism of action, pharmacokinetic, and pharmacodynamic profiles of tislelizumab.
EXPERT OPINION: Tislelizumab has higher affinity to PD-1 than pembrolizumab and nivolumab, potentially due to its differential PD‑1 binding orientation. Tislelizumab demonstrated encouraging efficacy results, long duration of response, and a manageable safety profile across multiple clinical trial...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Clinical Trials | Drugs & Pharmacology | Hodgkin's Disease | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer